How Cancer Will Lose: Genentech Posts Interactive Presentation on Cancer, with Glimpse at Future

How Cancer Will Lose: Genentech Posts Interactive Presentation on Cancer, with Glimpse at Future
GenentechGlobal biopharma Genentech, which became a member of the Roche Group in 2009, has been delivering on the biotechnology promise for more than 35 years, leading to the discovery, development, manufacture and commercialization of a range of medicines for treating patients with serious or life-threatening medical conditions, including various cancers. To demonstrate some of the progress achieved, Genentech has posted an interactive multimedia presentation online titled "Cancer Will Lose: A Visual Exploration of the Collective Efforts Against Cancer: Past, Present and Potential Future Breakthroughs." BergerD"Through collective efforts, progress is being made so that cancer will fade into history," said Dietmar Berger, M.D., senior vice president and Genentech's global head of clinical development for hematology and oncology, in the video prologue. "I know it may not always seem like it -- the disease will claim the lives of nearly 600,000 Americans this year -- but the tide is turning. Consider this: In 1975, fewer than half of people diagnosed with cancer lived five years past their diagnosis. By 2012, more than two-thirds of people with cancer saw five more birthdays. Over the past 40 years, millions of lives have been saved through lifestyle changes, education, screening, and groun
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.